IGF-1 Side Effects: Serious Risks of Mecasermin / Increlex
IGF-1 is not a casual wellness supplement. The approved recombinant human IGF-1 product Increlex (mecasermin) is indicated for narrowly defined pediatric growth failure in severe primary IGF-1 deficiency or growth-hormone gene deletion with neutralizing antibodies to GH. It is not a substitute for growth hormone for approved GH indications, and it carries serious label warnings.
IGF-1 is not a casual wellness supplement. The approved recombinant human IGF-1 product Increlex (mecasermin) is indicated for narrowly defined pediatric growth failure in severe primary IGF-1 deficiency or growth-hormone gene deletion with neutralizing antibodies to GH.
Key Takeaways
- IGF-1 (mecasermin / Increlex) is a prescription medicine for narrowly defined pediatric indications, not a bodybuilding or anti-aging product.
- It can cause severe hypoglycemia with seizures; it is administered around meals or snacks for this reason.
- Label warnings include hypersensitivity/anaphylaxis, intracranial hypertension, lymphoid hypertrophy, slipped capital femoral epiphysis, scoliosis progression, and malignant neoplasia.
- It is contraindicated in known hypersensitivity, closed epiphyses, and malignant neoplasia or a history of malignancy.
- Using IGF-1 for muscle, anti-aging, or unsupervised performance goals is not an approved use and can be dangerous.
IGF-1 (Mecasermin) at a Glance
| Property | Detail |
|---|---|
| Approved product | Increlex (mecasermin), recombinant human IGF-1 |
| Approved indication | Pediatric growth failure in severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies to GH |
| Not a substitute for | Growth hormone for approved GH indications |
| Mechanism | Insulin-like and growth-promoting effects; lowers blood glucose |
| Contraindications | Known hypersensitivity; closed epiphyses; malignant neoplasia / history of malignancy |
| Administration note | Given around meals/snacks to reduce hypoglycemia risk |
IGF-1 Side Effects: What Is Known
Mecasermin has insulin-like and growth-promoting effects that underpin both its therapeutic benefit and its risk. The label-defined warnings below are serious and explain why IGF-1 must only be used for approved indications under specialist supervision.
| Side Effect | Detail | Significance |
|---|---|---|
| Severe hypoglycemia | Low blood sugar with possible seizures | A major label warning; given with food/snacks to mitigate |
| Hypersensitivity / anaphylaxis | Rash, swelling, breathing difficulty | Can be life-threatening; contraindicated with known hypersensitivity |
| Intracranial hypertension | Severe headache, vision changes, nausea/vomiting | Requires urgent assessment |
| Malignant neoplasia | Tumour growth | Contraindicated in malignancy or history of malignancy |
| Lymphoid hypertrophy | Snoring, sleep apnea, tonsillar enlargement | Monitored on therapy |
| Skeletal complications | Slipped capital femoral epiphysis, scoliosis progression | Hip/knee pain or limp in children needs urgent review |
IGF-1 prescribed alongside other medicines?
Check the full regimen against your medication list. Allmeds flags hypoglycemia and high-risk interactions in minutes.
Safety Profile in Detail
| Dimension | Research summary |
|---|---|
| Mechanism | Mecasermin has insulin-like and growth-promoting effects. It can lower blood glucose and stimulate growth of tissues, which underpins both therapeutic benefit and risk. |
| Clinical evidence | FDA label safety information identifies serious warnings including severe hypoglycemia with seizures, hypersensitivity/anaphylaxis, intracranial hypertension, lymphoid tissue hypertrophy, slipped capital femoral epiphysis, scoliosis progression, malignant neoplasia, and benzyl-alcohol risk in infants. |
| Severity | High if misused, because hypoglycemia, neoplasia-related contraindications, intracranial hypertension, and pediatric skeletal complications are serious. |
| Symptoms to watch | Sweating, tremor, confusion, seizure, severe headache, visual changes, nausea/vomiting, snoring/sleep apnea, limp, hip/knee pain, allergic reaction, or abnormal growths. |
| Official guidance | Increlex is contraindicated in known hypersensitivity, closed epiphyses, and malignant neoplasia / history of malignancy. |
| Practical patient advice | IGF-1 should be used only for approved indications under specialist supervision. It should not be used for bodybuilding, anti-aging, or unsupervised performance goals. |
Common Questions About IGF-1 Side Effects
It can be, especially outside approved specialist use. Severe hypoglycemia and other serious risks are label warnings.
No. It is downstream of GH and has insulin-like effects; Increlex is not a substitute for GH indications.
Mecasermin can cause hypoglycemia and is administered around meals/snacks under label guidance.
This is not an approved use and can be dangerous.
Seizure, severe low blood sugar, severe headache/vision changes, allergic reaction, or hip/knee pain in children need urgent assessment.
Check IGF-1 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- European Medicines Agency. Product information and EPARs. ema.europa.eu.